# Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

> **NCT01182441** · PHASE3 · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 407 (actual)

## Conditions studied

- Atrial Fibrillation
- Stroke

## Interventions

- **DEVICE:** WATCHMAN Device
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT01182441
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-01
- **Final completion:** 2017-11
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01182441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01182441, "Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01182441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*